Attovia grants 140,000 stock options to CBO

Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026.

Rhea-AI Filing Summary

Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026. The options carry a $17.00 per share exercise price and expire on August 3, 2036. 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, she holds 140,000 stock options directly.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider Odrowaz Zaneta

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 140,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Key Figures

Stock options granted: 140,000 shares Exercise price: $17.00 per share Expiration date: August 3, 2036 +3 more

6 metrics

Stock options granted 140,000 shares Options to buy Attovia Therapeutics common stock granted to Chief Business Officer

Exercise price $17.00 per share Conversion or exercise price of the granted stock options

Expiration date August 3, 2036 Expiration date of the stock options granted on August 4, 2026

Initial cliff vesting 25% on August 4, 2027 Portion of options that vest one year after grant date

Remaining vesting period 36 months Remaining options vest in equal monthly installments over 36 months

Options held after transaction 140,000 options Total stock options directly held by Zaneta Odrowaz after the award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, derivative securities, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the options shall vest on August 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"reported as a grant or award acquisition of derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

equal monthly installments financial

"remaining options shall vest in equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Attovia Therapeutics (ATTO) grant to its Chief Business Officer?

Attovia Therapeutics granted 140,000 stock options to Chief Business Officer Zaneta Odrowaz at an exercise price of $17.00 per share. These options provide the right to buy common stock if vesting and other conditions are met.

What is the vesting schedule for the 140,000 ATTO stock options granted to Zaneta Odrowaz?

The options vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. Vesting is conditioned on her continued service to Attovia Therapeutics through those dates.

What is the exercise price and expiration date of the new ATTO stock options?

The granted stock options have an exercise price of $17.00 per share and an expiration date of August 3, 2036. They allow purchase of Attovia Therapeutics common stock if exercised after vesting and before expiration.

How many Attovia Therapeutics stock options does Zaneta Odrowaz hold after this Form 4 transaction?

After this award, Zaneta Odrowaz holds 140,000 stock options directly. This reflects the full amount of the new grant, as disclosed, and represents options to purchase Attovia Therapeutics common stock upon future exercise.

Was the Attovia Therapeutics (ATTO) option grant to Zaneta Odrowaz made under a 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating the grant is under a trading plan. The transaction is reported as a grant or award acquisition of derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/08/2026 - 02:11 PM Accepted by SEC EDGAR 08/06/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Odrowaz Zaneta

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	08/04/2026		A		140,000		(1)	08/03/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

	/s/ Steven Chan, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)